Xencor, CSL Enter Antibody Optimization Pact

Xencor, Inc. has entered into an antibody optimization collaboration with CSL, Ltd., under which CSL will have access to Xencor’s XmAb technology platform to enhance the ADCC effector function of its therapeutic antibodies.

Xencor has granted CSL several commercial licenses to move product candidates into development and commercialization that use Xencor’s XmAb technology. In addition to an undisclosed upfront payment, Xencor will receive development milestone payments and product royalties for each product commercialized using the Xencor technology.

“We are excited to collaborate with our CSL colleagues and enable their antibody products through the use of our XmAb technology,” commented Bassil Dahiyat, Ph.D., Xencor’s chief executive officer.

“We are pleased that the market is recognizing the preferred development friendly solution to increasing antibody effector function that Xencor offers,” commented James Posada, Ph.D., MBA, Xencor’s acting chief business officer.